DESIGN OF A DISCRETE CHOICE EXPERIMENT TO QUANTIFY CONSUMER PREFERENCES FOR CHRONIC HEART FAILURE MANAGEMENT PROGRAMS

White JA, Grifith BM, Minardi P, Carrington M, Stewart S

Griffith University, Meaadowbrook, Queensland, Australia; University of Queensland, Brisbane, Queensland, Australia; Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia

BACKGROUND: Consumer preferences are important to inform the efficient and responsive delivery of health-care services; particularly for the chronically ill. Chronic Heart Failure Management Programs (CHF-MPs) are effective at reducing morbidity and mortality and are arbitrarily applied in different ways and settings. We know very little of how consumer preferences surrounding the choice between CHF-MPs applied via the patient’s home or a specialist hospital clinic. The Discrete Choice Experiment (DCE) offers a method to systematically quantify the relative importance of different characteristics of a CHF-MP, from the patient’s perspective. OBJECTIVES: To describe the development of a DCE to quantify consumer preferences related to CHF-MPs. METHODS: A series of 12 semi-structured interviews were undertaken with patients enrolled in a clinical trial comparing home and clinic based CHF-MPs (the WHICH Study). Interviews explored the characteristics of a CHF-MP which were important to patients. These characteristics were then used as a basis for the design of the DCE instrument. A fractional factorial blocked design capable of estimating all main and one two-way interaction effect was utilized. RESULTS: Key themes identified by interview participants included delivery, communication, education, and nurturing. A CHF-MP DCE instrument was developed describing CHF-MPs in terms of characteristics including whether the same nurse is seen at each visit, the cost (including travel costs) of the nurse, and access to telephone or exercise/education support services. The DCE will now be pilot-tested before being used to elicit the preferences of approximately 300 patients enrolled in the WHICH Study. CONCLUSIONS: The WHICH Study is the first DCE study examining CHF-MPs. Patient preferences were found to be complex and multifaceted. The DCE design will form the basis of an ongoing study to be conducted with patients enrolled in the WHICH Study.

PERCEPTION OF PATIENTS ON WARFARIN THERAPY TOWARD PHARMACIST-MANAGED ANTICOAGULATION SERVICE IN AMBULATORY CARE SETTINGS IN SINGAPORE

Loo YC, Cho K, Law E, Lee SO

National University of Singapore, Singapore; *National Healthcare Group Pharmacy Singapore

OBJECTIVES: Patient perception has been shown to affect the success of pharmacist-managed clinics such as the anticoagulation clinic (ACC). However, such findings are yet to be elucidated in Singapore. The primary objective of this study was to assess patients' perceptions and acceptance of pharmacist-managed ACC in the primary care settings in Singapore. The secondary objective was to identify factors that may affect patient satisfaction and knowledge on warfarin therapy. METHODS: This was a cross-sectional, quality assurance, telephone survey conducted from September to December 2009. All patients referred to the pharmacists-managed ACC from nine primary care institutions for at least one visit were included, and those with hearing disability were excluded. The questionnaire was administered mainly in English, Chinese or Malay, and consisted of three sections: 1) patient demographics, 2) a 20-item, five-point likert scale patient satisfaction questions, and 3) a five-item warfarin knowledge questions. RESULTS: A total of 149 (39.9%) surveys were eligible for inclusion in analysis. Questions categorized into Friendly Explanation and Managing Therapy had mean scores of 3.64 ± 0.55 and 3.54 ± 0.60, respectively. Gender, ethnicity, education level and age were not associated with patient satisfaction. Age (p = 0.03) and education level (p = 0.01) were negatively and positively correlated with warfarin knowledge, respectively. CONCLUSIONS: Overall, patients found the ACC pharmacists to be friendly and were satisfied with the management of the service. Patient demographics did not associate with patient satisfaction. Age and education level, however, showed to affect warfarin knowledge.

BASELINE HEALTH-RELATED QUALITY OF LIFE STUDY IN HONG KONG CARDIAC PATIENTS UNDERGOING PERCUtaneous CORONARY INTERVENTION

Lee Y, Yan B, Yu CM

The Chinese University of Hong Kong, Shatin, Hong Kong

OBJECTIVES: To investigate the baseline quality of life of Hong Kong cardiac patients who had undergone percutaneous coronary intervention (PCI) and the baseline characteristics of these patients. METHODS: Eligible cardiac patients at the Prince of Wales Hospital having a PCI during March to September 2009 were recruited into the study while they were hospitalized for PCI. The generic short form 36 health survey (SF 36) and MacNew Heart Disease HRQOL questionnaire were used to assess the patient’s baseline quality of life. Patients’ social and clinical characteristics were also recorded. RESULTS: One hundred and twenty-two patients were recruited (male: 81%; mean age: 62.06 ±10.14). The highest incidence of PCI occurred in the age group of 50-59% (30%). Smoking patients reported with lower mean scores indicating a poorer quality of life. The mean scores of the 8 health domains of SF 36 were physical functioning (PF) 72.70, role physical (RP) 53.25, bodily pain (BP) 61.55, general health (GH) 49.83, vitality (VT) 47.85, social functioning (SF) 71.89, role emotional (RE) 72.67 and mental health (MH) 68.06. The mean physical component score (PCS) and mean mental component score (MCS) were 36.94 and 47.88, respectively. CONCLUSIONS: Risk factors including the male gender and advanced age contributed significantly to coronary heart disease. The presence of comorbidities, cigarette smoking, and long-standing CHD requiring elective PCI also contributed toward a poorer quality of life.

THE IMPACT OF SWITCHING PATIENTS TO ROSUVASTATIN ON HEALTH-CARE EXPENDITURE AND PREVENTION OF CARDIOVASCULAR DISEASE: A COHORT STUDY

Lin W, Chou LP, Kuo C

Chang Gung Christian University, Taiwan, Taiwan; *Sin-Lau Hospital, the Presbyterian Church of Taiwan, Tainan, Taiwan

OBJECTIVES: To assess the impact on the health-care expenditure and prevention of hospitalization of cardiovascular disease (CVD) for beneficiaries of Taiwan's National Health Insurance (NHI) scheme of rosuvastatin (Rsv) become available in NHI's benefit package in May, 2005. METHODS: Using NHI's claim data of a nationally representative random sample (consisting of 1 million of eligible beneficiaries) from 2004-2008, we classified patients >20 years of age who received other statins before and switched to Rsv during May 2005 to April 2006 into switch group (N = 1,440). Other patients who received statins therapy except Rsv before May 2005 and throughout 2008 were classified into control group. Using propensity score (PS), we selected match group (N = 1,039) from control group (N = 18,432) based on age, gender, prior ambulatory care expenditure, and comorbidities related to the probability of switching. The date of first claim for prescribing Rsv or other statins after May 2005 was the index date. Cumulative health expenditure after 1, 2, and 3 years from index date were compared between switch group and match group. Cox regression model controlling for age, sex, and comorbidities was applied to investigate the relative risk of hospitalization for CVD between two groups. RESULTS: Patients who switched to Rsv are significantly consumed more ambulatory care resources after 1-, 2-, and 3-year of switching ($348, $680, and $1030 more, respectively). Before PS matching, the relative risk of hospitalization CVD in switch group is significantly higher than control group (RR = 1.38, 95% CI = 1.12-1.70). After PS matching, the relative risk is still higher than match group (RR = 1.18, 95% CI = 0.881.58), but with less significance. CONCLUSIONS: RSV may be more cost-effective in lowering low-density lipoprotein cholesterol, but when taking the prevention of CVD hospitalization into account, the cost-effectiveness of declining lipoprotein should be considered much higher when cost is higher but benefit is not substantive.